GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (LTS:0ND5) » Definitions » Ending Cash Position

H. Lundbeck AS (LTS:0ND5) Ending Cash Position : kr5,113 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Ending Cash Position?

H. Lundbeck AS's Ending Cash Position for the quarter that ended in Mar. 2024 was kr5,113 Mil.

H. Lundbeck AS's quarterly Ending Cash Position increased from Sep. 2023 (kr4,248 Mil) to Dec. 2023 (kr5,010 Mil) and increased from Dec. 2023 (kr5,010 Mil) to Mar. 2024 (kr5,113 Mil).

H. Lundbeck AS's annual Ending Cash Position increased from Dec. 2021 (kr2,279 Mil) to Dec. 2022 (kr3,548 Mil) and increased from Dec. 2022 (kr3,548 Mil) to Dec. 2023 (kr5,010 Mil).

H. Lundbeck AS Ending Cash Position Historical Data

The historical data trend for H. Lundbeck AS's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Ending Cash Position Chart

H. Lundbeck AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,008.00 3,924.00 2,279.00 3,548.00 5,010.00

H. Lundbeck AS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,882.00 3,663.00 4,248.00 5,010.00 5,113.00

H. Lundbeck AS Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

H. Lundbeck AS's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3548+1462
=5,010

H. Lundbeck AS's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5010+103
=5,113

H. Lundbeck AS Ending Cash Position Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

H. Lundbeck AS (LTS:0ND5) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (LTS:0ND5) » Definitions » Ending Cash Position
Comparable Companies
OCSE:STENO ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 VTRS NBIX XSWX:SDZ SZSE:000538 BOM:500124 BOM:532321 TSE:4523 HKSE:03692 BOM:543904 NSE:DIVISLAB NSE:TORNTPHARM CTLT
Traded in Other Exchanges
HLBBF:USA HLUBF:USA 0ABR:UK HLUN A:Denmark HLUN B:Denmark LDBA:Germany
Address
Ottiliavej 9, Valby, DNK, 2500
Website
https://www.lundbeck.com
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS (LTS:0ND5) Headlines

No Headlines